"Akero Therapeutics to be Acquired by Novo Nordisk for Up to $5.2 Billion"

"Akero Therapeutics, Inc. has entered into a definitive agreement to be acquired by Novo Nordisk A/S for up to $5.2 billion in cash. Akero shareholders will receive $54.00 per share at closing, along with a contingent value right (CVR) that could provide an additional $6.00 per share upon U.S. regulatory approval of a treatment for compensated cirrhosis by 2031. The deal has been approved by Akero's Board and is expected to close by year-end, pending shareholder and regulatory approvals. Kirkland & Ellis provided legal counsel for the transaction."